MARINA sham-arm (n=238) | MEH matched (n=215) | MEH not matched (n=110) | UHB matched (n=44) | UHB not matched (n=7) | |
Patient demography | |||||
Sex n (%) | |||||
Female | 159 (66.8) | 128 (59.5) | 73 (66.4) | 32 (72.7) | 7 (100.0) |
Male | 79 (33.2) | 87 (40.5) | 37 (33.6) | 12 (27.3) | 0 (0.0) |
Age (years) n (%) | |||||
<65 | 11 (4.6) | 9 (4.2) | 6 (5.5) | 2 (4.5) | 0 (0.0) |
65–69 | 17 (7.1) | 19 (8.8) | 4 (3.6) | 1 (2.3) | 0 (0.0) |
70–74 | 50 (21.0) | 37 (17.2) | 14 (12.7) | 4 (9.1) | 0 (0.0) |
75~79 | 68 (28.6) | 58 (27.0) | 13 (11.8) | 4 (9.1) | 0 (0.0) |
80~84 | 64 (26.9) | 60 (27.9) | 20 (18.2) | 19 (43.2) | 0 (0.0) |
85+ | 26 (10.9) | 32 (14.9) | 53 (48.2) | 14 (31.8) | 7 (100.0) |
Ethnicity n (%) | |||||
White | 231 (97.1) | 97 (45.1) | 55 (50.0) | 39 (88.6) | 6 (85.7) |
Not white | 7 (2.9) | 118 (54.9) | 55 (50.0) | 5 (11.4) | 1 (14.3) |
Smoking status n (%) | |||||
Yes | 130 (54.6) | 110 (51.2) | 55 (50.0) | 33 (75.0) | 3 (42.9) |
No or unknown | 108 (45.4) | 105 (48.8) | 55 (50.0) | 11 (25.0) | 4 (57.1) |
Clinical features | |||||
Visual acuity (VA) (ETDRS letters) | |||||
Mean (SD) | 53.61 (14.06) | 52.92 (14.45) | 59.50 (18.36) | 52.55 (15.98) | 40.57 (20.98) |
Median (min, max) | 56.0 (3.0, 84.0) | 55.0 (0, 86.0) | 70.0 (11.0, 85.0) | 55.0 (0, 76.0) | 35.0 (11.0, 80.0) |
VA ≥70 ETDRS letters n (%) | |||||
Yes | 22 (9.2) | 16 (7.4) | 61 (55.5) | 8 (18.2) | 1 (14.3) |
No | 216 (90.8) | 199 (92.6) | 49 (44.5) | 36 (81.8) | 6 (85.7) |
VA ≤20 ETDRS letters n (%) | |||||
Yes | 4 (1.7) | 3 (1.4) | 3 (2.7) | 1 (2.3) | 1 (14.3) |
No | 234 (98.3) | 212 (98.6) | 107 (97.3) | 43 (97.7) | 6 (85.7) |
VA <25 ETDRS letters n (%) | |||||
Yes | 9 (3.8) | 12 (5.6) | 7 (6.4) | 1 (2.3) | 1 (14.3) |
No | 229 (96.2) | 203 (94.4) | 103 (93.6) | 43 (97.7) | 6 (85.7) |
Patient characteristics and clinical features for the MARINA sham-control cohort as well as the forecasted patients for the matched and non-matched MEH and UHB cohorts are shown.
MARINA, Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD; MEH, Moorfields Eye Hospital; UHB, University Hospitals Birmingham; VEGF, vascular endothelial growth factor.